Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically documented recurred/metastatic/unresectable biliary tract cancer, including gallbladder cancer, intrahepatic, extrahepatic cholangiocarcinoma, or ampulla of vater cancer.~2. Histologically confirmed HER2 positive biliary tract cancer. HER2-positive tumor was defined as either IHC 3+ or IHC 2+ in combination with ISH +, or ERBB2 amplification (≥6 copies) by tumor tissue NGS.~3. Recurred/metastatic/unresectable biliary tract cancer patient whose disease progression was confirmed by imaging modality after gemcitabine+cisplatin containing 1st line palliative chemotherapy regimen. Previous lines should be one or two (immunotherapy monotherapy not counted).~4. be willing and able to provide written informed consent/assent for the trial~5. be at least 19 years of age on day of signing informed consent~6. have measurable disease based on RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1~7. have a performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) Performance Scale~8. demonstrate adequate organ function~9. No severe valvular or arrhythmic cardiac disease with LVEF ≥ 50%~10. female subject of childbearing potential should have a negative urine or serum pregnancy or be willing to use birth control~Exclusion Criteria:~1. Previous treatment history of oxaliplatin containing chemotherapy, anti-HER2 targeting treatment (trastuzumab, neratinib, lapatinib, and etc)~2. has had a prior anti-cancer chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered.~3. has a known additional malignancy that is progressing or requires active treatment within 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin and thyroid cancer that has undergone potentially curative therapy or in situ cervical cancer~4. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis~5. has known history or evidence of any disease, treatment, or laboratory results that would inhibit the patient's participation to the study.~6. Has clinically significant cardiac disease, including congestive heart failure ≥ NYHA grade 2, uncontrolled hypertension, QTcF \> 470 msec or QT prolong syndrome, recent myocardiac infarction or unstable angina history~7. has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial~8. is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment~9. has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)~10. has known active Hepatitis B (HBsAg reactive and HBV DNA 100 ≥copies/ml) or Hepatitis C (anti-HCV reactive and HCV RNA \[qualitative\] is detected)~11. has received a live vaccine within 30 days of planned start of study therapy.~12. has an active infection requiring systemic therapy~13. has history of severe adverse event or allergic reaction to 5-FU, leucovorin, oxaliplatin or trastuzumab~14. need O2 supply or show dyspnea on rest due to advanced malignancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HERZUMA+mFOLFOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete